New Releases from NCBI BookshelfPembrolizumab (Keytruda): Indication: For the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 [Combined Positive Score (CPS) ≥ 1], as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy: Reimbursement Recommendation [Internet].Pembrolizumab (Keytruda): Indication: For the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 [Combined Positive Score (CPS) ≥ 1], as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Keytruda should be reimbursed by public drug plans for the treatment of adult patients […]
